Key facts
- This page summarizes Redmile Group, LLC's Form 4 filing for Adagio Therapeutics, Inc. (IVVD).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Aug 2021, 21:01.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Conversion of derivative security
Purchase
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Conversion of derivative security
Additional SEC filing notes
Section 16 status
Redmile Group, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Footnote F1
The Series C preferred stock (the "Series C Preferred") automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering for no consideration. The Series C Preferred had no expiration date.
Footnote F2
The Series C Preferred are directly owned by certain private investment vehicles managed by Redmile Group, LLC ("Redmile") and the reported securities may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Reporting Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.